Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis

Turkish Journal of Gastroenterology

Volumn 17, Issue 3, 2006, Pages 172-176

  Bölükbaş, Cengiz ^a,e   Bölükbaş, Füsun F ^a   Övünç, Oya ^b   Kiliç, Güray ^b   Dalay, Remzi ^b   Güven, Hatice ^b   Uras, Fikriye ^c   Yardimci, Turay K ^c   Sökmen, Mehmet H ^d   Agan, Ahmet F ^b   Pişkinpaşa, Nezih ^b  

^a HARRAN UNIVERSITY   (Turkey)

^b HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e Yenişehir Mah 4 ^*  (Turkey)

Author keywords

Atrophic gastritis; Eradication; Helicobacter pylori; Pepsinogen; Serology

Indexed keywords

AMOXICILLIN; BIOLOGICAL MARKER; CLARITHROMYCIN; IMMUNOGLOBULIN G; LANSOPRAZOLE; OMEPRAZOLE; PEPSINOGEN; PEPSINOGEN I; PEPSINOGEN II;

ADULT; ANTIBODY TITER; ARTICLE; ATROPHIC GASTRITIS; BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSCOPY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MALE; SEROLOGY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, BACTERIAL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PEPSINOGEN A; PEPSINOGEN C; PREDICTIVE VALUE OF TESTS; PYLORIC ANTRUM; SEROLOGIC TESTS;

EID: 34147184322     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kuipers EJ. In through the out door: serology for atrophic gastritis. Eur J Gastroenterol Hepatol 2003; 15: 877-9.
2. Lewin KJ, Warren JR. Unidentified curved bacillus on gastric epithelium in active chronic gastritis. Lancet 1984; 1: 1273-5.
3. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19: 37-43.
4. Varis O, Vale J, Siurala M. Is Helicobacter pylori involved in pathogenesis of the gastritis characteristic of pernicious anemia? Comparison between pernicious anemia relatives and duodenal ulcer relatives. Scand J Gastroenterol 1993; 28: 705-8.
5. Kawaguchi H, Haruma K, Komoto K, et al. Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol 1996; 91: 959-62.
6. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-8.
7. Tucci A, Biasco G, Paparo GF. Effect of eradication of Helicobacter pylori in patient with fundic atrophic gastritis. N Engl J Med 1997; 336: 957-8.
8. Borody TJ, Andrews P, Jankiewicz E, et al. Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. Am J Gastroenterol 1993; 88: 1266-8.
9. rd ed. New York: Raven Press, 1994; 1227-40.
10. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-6.
11. Samloff IM, Varis K, Ihamaki T, et al. Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal history. A study in relatives of patients with pernicious anemia. Gastroenterology 1982; 83: 204-9.
12. Samloff IM. Pepsinogens I and II: purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology 1982; 82: 26-33.
13. Hunter FM, Correa P, Fontham E, et al. Serum pepsinogens as markers of response to therapy for Helicobacter pylori. Dig Dis Sci 1993; 38: 2081-6.
14. th International Workshop on gastroduodenal pathology and Helicobacter pylori. Lisbon, Portugal, 1997; 12-14.
15. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
16. Webb PM, Hengels KJ, Moller H, et al. The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. EUROGAST Study Group. Gastroenterology 1994; 107: 1335-44.
17. Karnes WE Jr, Samloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991; 101: 167-74.
18. Fraser AG, Prewett EJ, Pounder RE, Samloff IM. Short report: twenty-four-hour hyperpepsinogenaemia in Helicobacter pylori-positive subjects is abolished by eradication of the infection. Aliment Pharmacol Ther 1992; 6: 389-94.
19. Mertz H, Sytnik B, Samloff IM, et al. Pepsinogen and pepsin in Helicobacter pylori infection. Gastroenterology 1992; 102: 124.
20. Presotto F, Sabini B, Cecchetto A, et al. Helicobacter pylori infection and gastric autoimmune diseases: is there a link? Helicobacter 2003; 8: 578-84.
21. Kokkola A, Kosunen TU, Puolakkainen P, et al. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS 2003; 111: 619-24.
22. Yoshida S, Saito D. Gastric premalignancy and cancer screening in high-risk patients. Am J Gastroenterol 1996; 91: 839-43.
23. Plebani M, Basso D, Cassaro M, et al. Helicobacter pylori serology in patients with chronic gastritis. Am J Gastroenterol 1996; 91: 954-8.
24. Uygun A, Kadayifci A, Kilinc R, Dagalp K. Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. Am J Gastroenterol 1999; 94: 3073-4.
25. Pamuk ON, Pamuk GE, Celik A, Uzunismail H. Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? Am J Gastroenterol 2000; 95: 1839-40.
26. Meuwissen SGM, Kuipers EJ. Helicobacter pylori, gastric cancer and gastric lymphoma. Postgraduate course EAGE, Paris: 1996; 57.
27. The EUROGAST Study Group. Epidemiology of and risk factors for Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 1993; 34: 1672-6.
28. Correa PA. Human model of gastric carcinogenesis. Cancer Res 1998; 48: 3554-60.
29. Genta RM. Helicobacter pylori, inflammation, mucosal damage, and apoptosis: pathogenesis and definition of gastric atrophy. Gastroenterology 1997; 113: 1-55.
30. Maconi G, Lazzaroni M, Sangaletti O, et al. Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer. Am J Gastroenterol 1997; 92: 1844-8.
31. Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16: 1449-56.